Inventor · disambiguated record
Alexander Redvers Eberlin
Also filed as: EBERLIN ALEXANDER · EBERLIN ALEXANDER R · EBERLIN ALEXANDER REDVERS
7 granted patents·4 pending applications·9 citations·filing 2006–2014
77Inventor score
Files withINFINITY PHARMACEUTICALS INC2LICARI PETER J2SPINIFEX PHARM PTY LTD2BOEHRINGER INGELHEIM PHARMA1BRISTOL MYERS SQUIBB CO1
Top patents by PatentIndex Score
11 records- 0182US9481667B2Salts and solid forms of isoquinolinones and composition comprising and methods of using the sameINFINITY PHARMACEUTICALS INC·Filed 2014·Granted Nov 1, 2016·4 cites·35 claims
- 0272US8927575B2Salts and solvates of a tetrahydroisoquinoline derivativeSPINIFEX PHARM PTY LTD·Filed 2013·Granted Jan 6, 2015·2 cites·11 claims
- 0370US8614227B2Salt and solvates of a tetrahydroisoquinoline derivativeMCCARTHY THOMAS DAVID·Filed 2011·Granted Dec 24, 2013·2 cites·30 claims
- 0466US7648976B217-allylamino-17-demethoxygeldanamycin polymorphs and formulationsBRISTOL MYERS SQUIBB CO·Filed 2006·Granted Jan 19, 2010·1 cites·47 claims
- 0559US9162985B2Salts and solvates of a tetrahydroisoquinoline derivativeSPINIFEX PHARM PTY LTD·Filed 2014·Granted Oct 20, 2015·0 cites·14 claims
- 0653US7872109B2Motilide polymorphsLICARI PETER J·Filed 2007·Granted Jan 18, 2011·0 cites·5 claims
- 0747US2009042847A117-allylamino-17-demethoxygeldanamycin polymorphs and formulationsKOSAN BIOSCIENCES INC·Filed 2008·Application pending·0 cites
- 0845US2011257215A1Novel co-crystal of tiotropium bromideBOEHRINGER INGELHEIM PHARMA·Filed 2007·Application pending·0 cites
- 0944US2016024051A1Salts and solid forms of isoquinolinones and composition comprising and methods of using the sameINFINITY PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 1043US8030282B2Motilide polymorphsLICARI PETER J·Filed 2010·Granted Oct 4, 2011·0 cites·10 claims
- 1132US2011086891A1Solid Forms of 2-(2,4-Difluorophenyl)-6-(1-(2,6-Difluorophenyl)Ureido)Nicotinamide)VERTEX PHARMA·Filed 2010·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →